Arvind Remedies Ltd
Arvind Remedies (ARL) engages in the drugs and pharmaceuticals business of India that manufactures capsules, liquids, ointments, tablets Syrup, Cream & Powders as well as Ayurvedic products at Kancheepuram in Tamilnadu.
- Market Cap ₹ 31.7 Cr.
- Current Price ₹ 4.70
- High / Low ₹ /
- Stock P/E
- Book Value ₹ -22.5
- Dividend Yield 0.00 %
- ROCE -8.56 %
- ROE -114 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -6.73% over last 3 years.
- Company has high debtors of 221 days.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Jun 2015 15m | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|
144 | 157 | 176 | 218 | 298 | 363 | 437 | 664 | 911 | 787 | 12 | |
133 | 143 | 160 | 198 | 267 | 321 | 369 | 531 | 734 | 842 | 107 | |
Operating Profit | 11 | 14 | 16 | 20 | 31 | 41 | 68 | 134 | 177 | -55 | -95 |
OPM % | 7% | 9% | 9% | 9% | 10% | 11% | 16% | 20% | 19% | -7% | -777% |
1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | -170 | -16 | |
Interest | 5 | 7 | 7 | 11 | 14 | 16 | 28 | 59 | 77 | 71 | 1 |
Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 13 | 14 | 29 | 20 |
Profit before tax | 5 | 5 | 7 | 7 | 15 | 23 | 37 | 63 | 86 | -325 | -133 |
Tax % | 39% | 20% | 26% | 33% | 31% | 26% | 48% | 35% | 32% | -2% | |
3 | 4 | 5 | 5 | 11 | 17 | 19 | 41 | 59 | -320 | -133 | |
EPS in Rs | 0.35 | 0.40 | 0.84 | 8.65 | -46.98 | -19.48 | |||||
Dividend Payout % | 42% | 30% | 25% | 27% | 12% | 20% | 17% | 12% | 9% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 22% |
TTM: | -98% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 32% |
Stock Price CAGR | |
---|---|
10 Years: | -10% |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 0% |
3 Years: | -7% |
Last Year: | -114% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Jun 2015 | |
---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 26 | 26 | 26 | 26 | 26 | 48 | 48 | 48 | 68 | 68 |
Reserves | 12 | 15 | 19 | 22 | 69 | 73 | 95 | 146 | 211 | -110 |
57 | 85 | 86 | 104 | 123 | 184 | 362 | 520 | 623 | 750 | |
22 | 31 | 42 | 40 | 50 | 65 | 98 | 128 | 189 | 77 | |
Total Liabilities | 117 | 158 | 173 | 192 | 268 | 370 | 603 | 842 | 1,092 | 784 |
26 | 29 | 30 | 35 | 36 | 45 | 242 | 251 | 349 | 275 | |
CWIP | 5 | 27 | 35 | 20 | 38 | 19 | 49 | 37 | 67 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 6 | 3 |
86 | 102 | 108 | 138 | 194 | 306 | 309 | 551 | 670 | 505 | |
Total Assets | 117 | 158 | 173 | 192 | 268 | 370 | 603 | 842 | 1,092 | 784 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Jun 2015 | |
---|---|---|---|---|---|---|---|---|---|---|
-9 | 10 | 16 | -13 | -8 | 12 | 7 | 13 | -60 | -151 | |
-7 | -27 | -12 | 8 | -21 | -62 | -158 | -123 | -21 | 105 | |
7 | 20 | -8 | 5 | 42 | 55 | 152 | 112 | 63 | 44 | |
Net Cash Flow | -9 | 4 | -3 | -0 | 13 | 6 | 1 | 2 | -18 | -2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Jun 2015 | |
---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 135 | 152 | 143 | 140 | 131 | 135 | 142 | 133 | 133 | 221 |
Inventory Days | 66 | 75 | 78 | 65 | 66 | 68 | 92 | 89 | 104 | 3 |
Days Payable | 23 | 47 | 69 | 50 | 48 | 49 | 40 | 49 | 50 | 4 |
Cash Conversion Cycle | 178 | 179 | 152 | 155 | 149 | 155 | 194 | 173 | 187 | 221 |
Working Capital Days | 178 | 170 | 149 | 176 | 171 | 162 | 174 | 177 | 206 | 214 |
ROCE % | 11% | 11% | 13% | 16% | 15% | 16% | 20% | 20% | -9% |